Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
Rhea-AI Summary
Sana Biotechnology (NASDAQ: SANA) announced an oral presentation of preclinical data for SG293, its CD19-directed in vivo CAR T candidate, accepted at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, May 11–15, 2026 in Boston.
The presentation, titled "Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293", is scheduled for May 12, 2026, 8:15–8:30 a.m. ET during the session on advancing in vivo gene delivery with non-AAV viral vector systems (Abstract No. 20; MCEC Room 257AB).
Positive
- None.
Negative
- None.
News Market Reaction – SANA
On the day this news was published, SANA gained 2.76%, reflecting a moderate positive market reaction. This price movement added approximately $24M to the company's valuation, bringing the market cap to $902.25M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SANA is down 4.36% with no peers in the momentum scanner. Among high-affinity peers, most are negative (e.g., NKTR down 5.64%, QURE down 1.86%, URGN down 2.10%) while TSHA is up 1.57%, indicating mixed, stock-specific trading rather than a clear sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-04-13 | Strategic partnership | Positive | +8.4% | Mayo Clinic equity-backed collaboration to accelerate SC451 for type 1 diabetes. |
| 2026-04-06 | Sector commentary | Neutral | +0.6% | Industry article on shifting focus to cell therapy manufacturing capabilities. |
| 2026-03-13 | Clinical data update | Positive | +8.7% | 14‑month follow-up showing sustained UP421 islet cell function without immunosuppression. |
| 2026-03-03 | Earnings and updates | Neutral | -2.8% | Q4/FY25 results, financing proceeds, cash runway into late 2026, and impairment charge. |
| 2026-02-23 | Investor conferences | Neutral | +3.9% | Announcements of March 2026 investor conference presentations and webcast availability. |
Recent stock reactions have generally been positive on clinical and partnership updates, with a modest decline on the latest earnings release.
Over the last few months, SANA has highlighted multiple catalysts. A Mayo Clinic collaboration focused on SC451 and type 1 diabetes on 2026-04-13 saw the stock rise 8.41%. Continued positive diabetes data from UP421 on 2026-03-13 led to an 8.74% gain. Q4 and full‑year 2025 results on 2026-03-03, which included financing updates and a $44.6M impairment, coincided with a -2.8% move. Today’s ASGCT preclinical presentation fits into this cadence of scientific and platform visibility events.
Regulatory & Risk Context
Sana has an effective S-3ASR shelf filed on 2026-03-03, supporting an at-the-market program of up to $150,000,000 in common stock with TD Securities (USA) LLC (TD Cowen) and carrying forward $216,385,563 of unsold securities from a prior Form S‑3. The shelf has already been used at least once, as indicated by the 424B5 prospectus supplement on 2026-04-13.
Market Pulse Summary
This announcement highlights an accepted ASGCT 2026 oral presentation for SG293, Sana’s CD19-directed in vivo CAR T candidate, emphasizing preclinical data in NHPs and positioning within a session on non-AAV gene delivery. It follows recent collaboration, clinical, and financing updates that extended runway into at least late 2026. Investors may watch for detailed efficacy and safety readouts from this preclinical work and subsequent first-in-human SG293 data, while also monitoring additional usage of the effective $150,000,000 ATM shelf and any new financing-linked announcements.
Key Terms
in vivo car t medical
car-t cells medical
cd19-directed medical
in vivo gene delivery medical
non-aav viral vector medical
AI-generated analysis. Not financial advice.
SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, its CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA.
Oral Presentation:
| Title: | Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293 |
| Summary: | SG293 represents a differentiated approach for enabling potent and precise in vivo CAR T therapy for both oncology and autoimmune indications, potentially avoiding key off-target concerns. |
| Session: | Advancing in vivo gene delivery with non-AAV viral vector systems |
| Session Location: | MCEC Room 257AB (Level 2) |
| Session Date/Time: | Tuesday, May 12, 2026; 8:00 – 9:45 a.m. ET |
| Presentation Time: | 8:15 – 8:30 a.m. ET |
| Abstract Number: | 20 |
The ASGCT abstract is available to the public at: https://annualmeeting.asgct.org.
About SG293
SG293, which uses Sana’s proprietary fusogen-based delivery technology, is a CD8-targeted fusosome that delivers to CD8+ T cells the genetic material to make CD19-directed CAR T cells while avoiding potentially troublesome delivery to tissues such as the liver. The fusogen technology is designed to enable cell-specific delivery of material that integrates into the DNA of the target cell. Sana intends to explore SG293 in both B-cell cancers and B-cell mediated autoimmune diseases.
About Sana
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; expectations for the Company’s participation and presentation at the American Society of Gene & Cell Therapy 2026 Annual Meeting, including the content of such presentation; and expectations for and the potential benefits of its SG293 program and the fusogen technology, including preclinical, clinical, and regulatory development plans, the potential significance and impact of preclinical data, and potential indications for SG293. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others: the risks inherent in drug development such as those associated with the initiation, cost, timing, progress, and results of the Company’s current and future research and development programs and preclinical and clinical trials, the risk that results of preclinical studies may not be predictive of results of potential future studies, and the risk that our product candidates may not be successfully developed or commercialized in any indication; and risks related to economic, market, and other disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s Securities and Exchange Commission (“SEC”) reports, including but not limited to its Annual Report on Form 10-K dated March 3, 2026. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
